Ultrasound Molecular Imaging of VEGFR2 in a Rat Prostate Tumor Model Using BR55

Tardy, Isabelle; Pochon, Sibylle; Theraulaz, Martine; Emmel, Patricia; Passantino, Lisa; Tranquart, F.; Schneider, Michel

doi:10.1097/rli.0b013e3181ee8b83

Cited by 116 publications

(84 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, targeting peptides and antibodies can also be coupled using nonimmunogenic linkers. This was recently demonstrated with clinically applicable poly-n-butylcyanoacrylate MBs based on a peptide ligand for specific imaging of E-selectin expression in tumor blood vessels, 39 as well as with angiogenesis-specific VEGFR 2 -MBs in molecular imaging of breast and prostate cancer, 40,41 and with P-and E-selectin-targeted MBs in inflammatory bowel disease 42 and myocardial infarction. 43 Following these examples of clinically translatable molecular ultrasound contrast agents, the generation of a MB VCAM-1 with covalently attached targeting ligands would be a logical and practicable next step for future clinical implementation.…”

Section: Discussionmentioning

confidence: 99%

Noninvasive Molecular Ultrasound Monitoring of Vessel Healing After Intravascular Surgical Procedures in a Preclinical Setup

Curaj

Fokong

et al. 2015

ATVB

View full text Add to dashboard Cite

Objective— Cardiovascular interventions induce damage to the vessel wall making antithrombotic therapy inevitable until complete endothelial recovery. Without a method to accurately determine the endothelial status, many patients undergo prolonged anticoagulation therapy, denying them any invasive medical procedures, such as surgical operations and dental interventions. Therefore, we aim to introduce molecular ultrasound imaging of the vascular cell adhesion molecule (VCAM)-1 using targeted poly- n -butylcyanoacrylate microbubbles (MB VCAM-1 ) as an easy accessible method to monitor accurately the reendothelialization of vessels. Approach and Results— ApoE −/− mice were fed with an atherogenic diet for 1 and 12 weeks and subsequently, endothelial denudation was performed in the carotid arteries using a guidewire. Molecular ultrasound imaging was performed at different time points after denudation (1, 3, 7, and 14 days). An increased MB VCAM-1 binding after 1 day, a peak after 3 days, and a decrease after 7 days was found. After 12 weeks of diet, MB VCAM-1 binding also peaked after 3 days but remained high until 7 days, indicating a delay in endothelial recovery. Two-photon laser scanning microscopy imaging of double fluorescence staining confirmed the exposure of VCAM-1 on the superficial layer after arterial injury only during the healing phase. After complete reendothelialization, VCAM-1 expression persisted in the subendothelial layer but was not reachable for the MB VCAM-1 anymore. Conclusion— Molecular ultrasound imaging with MB VCAM-1 is promising to assess vascular damage and to monitor endothelial recovery after arterial interventions. Thus, it may become an important diagnostic tool supporting the development of adequate therapeutic strategies to personalize anticoagulant and anti-inflammatory therapy after cardiovascular intervention.

show abstract

Section: Discussionmentioning

confidence: 99%

Noninvasive Molecular Ultrasound Monitoring of Vessel Healing After Intravascular Surgical Procedures in a Preclinical Setup

Curaj

Fokong

et al. 2015

ATVB

View full text Add to dashboard Cite

show abstract

“…Recently, Tardy et al [ 129 ] have designed BR55, a VEGFR-2 specifi c UCA, showing that this agent not only provides information on tissue perfusion during the early vascular phase, but also it highlights the sites of active angiogenesis in rat prostate tumour.…”

Section: A B C R U S S O E T a Lmentioning

confidence: 99%

Angiogenesis in prostate cancer: onset, progression and imaging

et al. 2012

View full text Add to dashboard Cite

What's known on the subject? and What does the study add?Today, angiogenesis is known to play a key role in cancer growth and development. Emerging cancer treatments are based on the suppression of angiogenesis, and modern imaging techniques investigate changes in the microvasculature that are caused by angiogenesis. As for other forms of cancers, angiogenesis is well recognised as a fundamental process in the development of prostate cancer.The novelty of this extensive report on angiogenesis in cancer, with particular attention on prostate cancer and the imaging techniques able to detect it, is the new prospective to the subject. In contrast with the other available reviews, this report goes from ‘theory’ to ‘practice’, establishing a clear link between angiogenesis development and imaged angiogenesis features. Once the key role of angiogenesis in the development of cancer and in particular prostate cancer has been fully described, attention is turned to the current imaging methods with the potential to assess the angiogenesis process and, as a consequence, to detect and localise prostate cancer. As confirmed by all available statistics, cancer represents a major clinical and societal problem in the developed world. The form of cancer with the highest incidence in men is prostate cancer. For prostate cancer, as well as for most forms of cancer, detection of the disease at an early stage is critical to reduce mortality and morbidity. Today, it is well known that pathological angiogenesis represents a crucial step in cancer development and progression. Comparable with most forms of cancer, angiogenesis also plays a fundamental role for prostate cancer growth. As a consequence, angiogenesis is an ideal target not only for novel anti‐angiogenic therapies, but also for modern imaging techniques that aim at cancer localisation by detection of angiogenic microvascular changes. These techniques are mainly based on magnetic resonance, ultrasound, and nuclear imaging. This paper provides a comprehensive review of the available studies on angiogenesis in prostate cancer and its use by modern and emerging imaging techniques for prostate cancer localisation.

show abstract

“…Results obtained from the selected ROI represented an approximately linear depiction of the backscattered intensity. The average of the linearized intensities of all the pixels in the ROI was calculated to produce a time-signal intensity curve, where the intensity is theoretically linked to microbubble concentration [13].…”

Section: Imaging Analysismentioning

confidence: 99%

Assessment of Early Tumor Response to Cytotoxic Chemotherapy With Dynamic Contrast-Enhanced Ultrasound in Human Breast Cancer Xenografts

Zhou

Wang

Zheng

et al. 2013

Ultrasound in Medicine & Biology

View full text Add to dashboard Cite

There is a strong need to assess early tumor response to chemotherapy in order to avoid adverse effects from unnecessary chemotherapy and allow early transition to second-line therapy. This study was to quantify tumor perfusion changes with dynamic contrast-enhanced ultrasound (CEUS) in the evaluation of early tumor response to cytotoxic chemotherapy. Sixty nude mice bearing with MCF-7 breast cancer were administrated with either adriamycin or sterile saline. CEUS was performed on days 0, 2, 4 and 6 of the treatment, in which time-signal intensity (SI) curves were obtained from the intratumoral and depth-matched liver parenchyma. Four perfusion parameters including peak enhancement (PE), area under the curve of wash-in (WiAUC), wash-in rate (WiR) and wash-in perfusion index (WiPI) were calculated from perfusion curves and normalized with respect to perfusion of adjacent liver parenchyma. Histopathological analysis was conducted to evaluate tumor perfusion, tumor cell density, microvascular density (MVD) and proliferating cell density. Significant decreases of tumor normalized perfusion parameters (i.e., nPE, nWiAUC, nWiR and nWiPI) were noticed between adriamycintreated and control groups (P,0.01) 2 days after therapy. There were significant differences of tumor volumes between control and treated groups on day 6 (P,0.001) while there were no significant differences in tumor volume on days 0, 2 and 4 (P.0.05). Significant decreases of tumor perfusion, tumor cell density, MVD and proliferating cell density were seen in adrianycin-treated group 2 days after therapy when compared to control group (P,0.001). Dynamic CEUS for quantification of tumor perfusion could be used for early detection of cancer response to cytotoxic chemotherapy prior to notable tumor shrinkage.

show abstract

Ultrasound Molecular Imaging of VEGFR2 in a Rat Prostate Tumor Model Using BR55

Cited by 116 publications

References 26 publications

Noninvasive Molecular Ultrasound Monitoring of Vessel Healing After Intravascular Surgical Procedures in a Preclinical Setup

Noninvasive Molecular Ultrasound Monitoring of Vessel Healing After Intravascular Surgical Procedures in a Preclinical Setup

Angiogenesis in prostate cancer: onset, progression and imaging

Assessment of Early Tumor Response to Cytotoxic Chemotherapy With Dynamic Contrast-Enhanced Ultrasound in Human Breast Cancer Xenografts

Contact Info

Product

Resources

About